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COMPARISON of the effectiveness of alternative treatments is most reliably
done in controlled clinical trials where treatments are allocated at random.
Amongst the many deficiencies of chemotherapy for cancer is the difficulty of
assessing reports of uncontrolled observations. The derogatory label of
" polypharmacy " might well be applied to many such reports, especially in view
of the apparent feasibility of organising controlled clinical trials in this field.
The high incidence of cancer of the lung in Great Britain and especially in
this region of Scotland, the development of the chronofusor-a portable infusion
pump-and increasing interest in the cellular kinetics of neoplasms, together
suggested a study of continuous prolonged infusion of antimetabolites for
unresectable tumours of this sort. Preliminary reports (Anderson, 1966;
Anderson, Smith and Hutchison, 1966; Anderson and Hutchison, 1968) described
the technique, complications and early results. This paper presents the clinical
and statistical design of the trial along with definitive results.
Chemotherapeutic regimes
The paucity of controlled trials makes it difficult logically to assess the places
of different agents in the treatment of carcinoma of the lung. However it seems
that alkylating agents, and particularly nitrogen mustard, have been more
frequently accorded success than have antimetabolites or other cytotoxins.
Unfortunately alkylating agents are unstable in solution, the half-life of nitrogen
mustard in aqueous solution is only twenty minutes, and it is not possible to
charge the chronofusor reservoir with a stable concentrated solution for infusion
during a period ofdays. Thus continuous prolonged infusion ofnitrogen mustard
could not be tested. This agent was therefore used in the conventional manner
for treatment of a control group. Ideally the control group should have no
treatment at all or a placebo treatment. Neither of these seemed ethically
admissible in dealing with cancer. Therefore it was decided to compare two
treatments, each thought to give some benefit. The regime to be tested against
the control treatment of nitrogen mustard consisted of intravenous infusion of
the antimetabolites, 5-fluorouracil, methotrexate and the ethyl hydrazide of
podophyllic acid (SPI), sequentially during periods of many months. Each
of these agents has been reported as effective in some cases of cancer of the lung
and it was felt that changing from one drug to the other would compensate in
some degree for the deficiencies in our ability to assess the sensitivities of cancers
to different drugs.
It was clear that currently available drugs would be unlikely to eliminate or
cure advanced pulmonary cancer. Therefore the regimes were planned to slowREGIONAL CHEMOTHERAPY FOR LUNG CANCER
the rates ofgrowth oftumours and to make the lifetime remaining to each patient
as comfortable and as useful as possible. That is, a custodial rather than an
ablative attitude was chosen, a concept well established in microbial chemotherapy
but not in cancer where agent sensitivity is unknown and where there is no reliable
specificity of action. Since life is already endangered in these patients iatrogenic
toxicity which would limit the patients' activity or further jeopardise the quality
of life was judged an unacceptable part of a regime intended to be a treatment.
The doses of antimetabolites were determined accordingly, the daily doses being
small, but the total dose given to each patient would have been supralethal as a
single exposure.
METHODS OF TREATMENT
Nitrogen mustard
0 5 mg./kg. of body weight was given as a single large dose by intravenous
injection using standard methods. This was followed by the small dose of 1 mg.
only, once weekly, to copy the effect of the prolonged exposure planned in the
test group. All solutions of nitrogen mustard were made up immediately before
injection so that no opportunity for degradation to inactive products was allowed.
Promazine hydrochloride (Sparine: Wyeth) 50 mg. by intramuscular injection or
by mouth was given before each dose of nitrogen mustard.
Antimetabolite regime
All of the patients assigned to this method of treatment were firstly given
5-fluorouracil 250 mg. daily. This was continued until tomography or sympto-
matic changes indicated an increase in the volume of the tumour or progression
of the disease. Methotrexate 5-10 mg. daily was then given until increased
tumour volume was again detected, when treatment with SPI 40 mg. daily was
commenced. Thus every patient received one or more of these agents separately
in the pre-arranged sequence until it became evident that the terminal phase of
life had been reached. At this time the administration of promazine hydro-
chloride by continuous infusion proved a useful palliative measure. These agents
were given by constant infusion into the superior vena cava via a permanently
indwelling, fine Teflon catheter, through which 5 ml. of solution was propelled
daily by means of the chronofusor as previously described (Anderson and
Hutchison, 1968).
DESIGN OF THE TRIAL
The trial was constructed upon the following points, designed to minimise
the inherent variability of the population presenting with cancer of the lung, and
to eliminate bias in a valid sequential comparison ofthe two treatments described
above.
Admission criteria
(1) Patients whose cancers had a squamous-cell histology were admitted.
The evidence from direct endobronchial biopsy was preferred but where this was
not possible the diagnosis based upon sputum cytology was accepted initially and
confirmatory evidence was sought at post-mortem.
(2) Only tumours which were unresectable because of involvement of media-
stinal or supraclavicular lymph nodes were admitted.
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(3) No patients with extra-thoracic disease, excluding supraclavicular lymph
node involvement, were admitted. Evidence of dissemination of cancer was
sought by extensive clinical and laboratory investigations with the addition of a
radiological skeletal survey.
(4) Only patients between 45 and 75 years of age were admitted.
(5) Patients had to be intelligent and fit enough for the management of a
chronofusor. Also a chronofusor had to be available if the patient were to be
admitted to the trial, in case the patient were assigned to the test group.
Allocation
Following admission to the trial on the basis ofthe above criteria each patient
was randomly assigned to the test group or the control group. An allocation
list, consisting of a series ofindex cards each marked with a symbol for treatment
with either the chronofusor or nitrogen mustard, was used. Each successive
group of four cards contained an equal number of allocations to each treatment
group. Each block of four was mixed in an unknown and random order so that
when a patient was admitted and the next card in order drawn the allocation was a
matter of chance. Furthermore since each block of four consisted of two groups
oftwo allocations to each treatment group, an analysis ofpairs ofsubjects treated
more or less contemporaneously could be made without introducing the bias of
knowledge of the treatment to be applied to the second member of each pair,
as would result from simple alternative allocation.
ASessment
The intra-pair measurement upon which each treatment was assessed was the
vital status-whether each patient was alive or dead-six months after the start
of treatment. If one patient was alive and the other dead, the result was
considered as a " preference " for the treatment given to the living patient.
RESULTS
The data assessed in the way described above are presented in Table I where
the patients are listed in the order oftheir admission to the trial and their random
assignation to a treatment group. Each figure in the survival column represents
the number ofcomplete months that the patient lived after the start of treatment.
The only side-effects encountered were two instances of megaloblastic anaemia,
previously described (Anderson, Smith and Hutchison, 1966; Anderson and
Hutchison, 1968).
An analytical graph was constructed on ordinary squared graph paper for a
design having a two-sided 5% significance level. The slopes of the boundaries
AB, AC, DE and FG in Fig. 1 were calculated from the equations and tables
described by Armitage (1960). The design was chosen to have power sufficient to
detect with 95% probability a difference in the survival probabilities represented
by the values 0*5 and 0*2, with the probability of a preference for one treatment
being 0-8. During this trial the sample path was plotted as a zig-zag line starting
at 0 and moving one unit diagonally upwards for each chronofusor preference and
one unit downwards for each nitrogen mustard preference. If the sample path
had crossed the line DE the chronofusor treatment would have been better than
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the nitrogen mustard treatment at the pre-determined degree of statistical
significance. The reverse would have held if the sample path crossed the line
FG. In this trial the sample line entered the area enclosed by the two middle
TABLE I.-Survival Data ofPatients in Both Treatment Groups
Preference at six months
Patient
=- A Treatment Survival Nitrogen
Sex Age Assigned months mustard Chronofusor
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F 54
M 69
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M 60
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M 63
F 50
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F 55
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M 58
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FIG. 1.-The graph for sequential analysis of the data. The slopes AB, AC, DE and FG were
calculated by the methods of Armitage (1960) for an open design having a two-sided
significance level 2ax = 0 05. The sample path is the zig-zag line starting at 0 and moving
one unit diagonally upwards for each chronofusor preference and one unit diagonally
downwards for each nitrogen mustard preference. Since the sample path enters the area
enclosed by the lines AB and AC the difference between the two treatments is not statistically
significant at the 5% level.
lines AB and AC which means that under the experimental conditions already
defined the difference between the two treatments is not statistically significant
at the 5 0 level.
DISCUSSION
The aptness of sequential analysis for clinical trials of therapies depends upon
the serial entry of patients to the trial and the continuous scrutiny of the results.
These are two conditions occurring naturally in medical practice. In addition,
the ethical demand for the most effective treatment can often be met at an earlier
stage of assessing observations as they become available, rather than by awaiting
the completion of a trial involving a predetermined number of patients. Thus
the burden of our ignorance is inflicted upon the smallest number of patients and
the unnecessary use of inferior treatments is avoided.
Cancer of the lung was studied for three reasons:
(1) These tumours are infrequently resectable and in general poorly radio-
sensitive, thus there is a need for the development of other forms of treatment,
and this is an ever-increasing need as judged by the rising incidence ofthe disease,
despite the commonly-known indictment of cigarette smoking.
(2) There are a number of favourable reports of intravenous chemotherapy
(Galton, 1958; Karnofsky, 1959; Goldman, 1963; Barran, Helm and King, 1965).
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Bronchial arterial infusion chemotherapy has also been effective but it is unlikely
that prolonged infusion by this route would be widely applicable. In two studies
(Kahn, Paul and Rheinlander, 1965; Wirtanen and Ansfield, 1968) only one-
quarter of the attempts to achieve selective bronchial arterial infusion were
successful and infusions could not be maintained longer than two to fifteen days.
Unwanted effects may be associated with bronchial arterial infusion according to
reports of para-oesophageal, intercostal and spinal anastomoses by Viamonte,
Parks and Smoak (1965). The same detailed radiological study and other
anatomical dissections (Wright, 1938) demonstrate the unpredictability of both
bronchial and pulmonary vascularisation of primary pulmonary neoplasms and
the frequency with which more than one bronchial artery may supply each lung.
Intravenous chemotherapy was chosen for this study because it is applicable to
all patients. The naturally high concentration of an intravenous infusate in the
pulmonary circulation may be advantageous.
(3) The poor prognosis in cancer ofthe lung means that a proportionately large
prolongation of life is obvious at a relatively early time of assessment such as
six months after starting the treatment of each patient.
Although the assessment of the " vital " value of constant prolonged chemo-
therapy is negative there are a number of positive aspects to this trial. The
applicability of the general principles of statistical control to therapeutic trials
in cancer of the lung, and the specific value of Armitage's Sequential Analysis,
have been demonstrated. It seems that this method could usefully form the
basis of future assessments of new therapeutic regimes. The highest standards
of patient care have not been sacrificed upon the altar of science, on the contrary
they may have been enhanced by the emotional benefits felt even by intelligent
patients reassured by the therapeutic activity and the interest in their problems.
This assessment can be readily dismissed by the scientific purist as " only psycho-
logical " and not real in terms ofprolonged survival, but this type ofpsychological
support is a reality to the patient. Any simple technique of drug administration
can provide support that encouraging words alone cannot give.
This trial has not shown that either regime gives a longer survival than the
natural course of the disease determines. A useful comparison is with patients
receiving palliative treatment in the form of radiotherapy, chemotherapy or
surgery. The Cancer Registration Bureau of the Western Regional Hospital
Board in Scotland published suitable data (1967). The twelve-month survival
for these palliative treatments in the triennium 1962-64 was 15-2% and for
untreated patients it was 13*9%, whereas the overall twelve-month survival rate
in the series of patients described herein is 24.9%. Comparison of these two
groups is not statistically valid but if the view that placebo or no-treatment
groups are ethically inadmissible in cancer is held then no other assessment of
this sort is available.
There is a widespread resistance amongst doctors to accept that it is more
ethical to apply new treatments randomly according to a judicious protocol than
to treat a selected series of patients. This attitude has one of two possible
results. Either an effect is not demonstrated and the treatment is discarded,
or non-randomised methods are continued because there has been apparent benefit
and it is thought unethical to deprive future patients of a possibly beneficial
treatment. The excuse that impossibly large numbers of patients are required
to allow definitive conclusions to be drawn is often made. Many trials, including
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that reported in this paper, show this to be untrue, and such an argument could
more forcibly be applied to those who make judgements upon large uncontrolled
series of patients. This unwillingness to apply the principles of clinical measure-
ment more widely has no easy solution, meanwhile it is clear that the necessitous
field of cancer therapy requires new regimes and adequate evaluation of them in
trials designed to answer specific questions.
SUMMARY
A controlled clinical comparison oftwo methods of chemotherapy for cancer of
the lung has been assessed by the sequential method of Armitage. No difference
at the 5% level of statistical significance, in terms of patient survival, exists
between the two treatments. It is concluded that this type of clinical measure-
ment oftreatments for cancer does not jeopardise standards ofpatient careandthat
it forms a sound basis for the assessment of new treatments.
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